Abstract

Despite known histological, biological, and clinical differences between lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), relatively little is known about the spatial differences in their corresponding immune contextures. Our study of over 1000 LUAD and LUSC tumors revealed that computationally derived patterns of tumor-infiltrating lymphocytes (TILs) on H&E images were different between LUAD (N = 421) and LUSC (N = 438), with TIL density being prognostic of overall survival in LUAD and spatial arrangement being more prognostically relevant in LUSC. In addition, the LUAD-specific TIL signature was associated with OS in an external validation set of 100 NSCLC treated with more than six different neoadjuvant chemotherapy regimens, and predictive of response to therapy in the clinical trial CA209-057 (n = 303). In LUAD, the prognostic TIL signature was primarily comprised of CD4+ T and CD8+ T cells, whereas in LUSC, the immune patterns were comprised of CD4+ T, CD8+ T, and CD20+ B cells. In both subtypes, prognostic TIL features were associated with transcriptomics-derived immune scores and biological pathways implicated in immune recognition, response, and evasion. Our results suggest the need for histologic subtype-specific TIL-based models for stratifying survival risk and predicting response to therapy. Our findings suggest that predictive models for response to therapy will need to account for the unique morphologic and molecular immune patterns as a function of histologic subtype of NSCLC.

Details

Title
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome
Author
Ding, Ruiwen 1 ; Prasanna, Prateek 2 ; Corredor, Germán 3   VIAFID ORCID Logo  ; Barrera, Cristian 1 ; Zens, Philipp 4 ; Lu, Cheng 1 ; Velu, Priya 5 ; Leo, Patrick 1   VIAFID ORCID Logo  ; Beig, Niha 1 ; Li, Haojia 1 ; Toro, Paula 1 ; Berezowska, Sabina 6 ; Baxi, Vipul 7 ; Balli, David 7 ; Belete, Merzu 7 ; Rimm, David L. 8   VIAFID ORCID Logo  ; Velcheti, Vamsidhar 9 ; Schalper, Kurt 8 ; Madabhushi, Anant 3 

 Case Western Reserve University, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847) 
 Stony Brook University, New York, USA (GRID:grid.36425.36) (ISNI:0000 0001 2216 9681) 
 Case Western Reserve University, Cleveland, USA (GRID:grid.67105.35) (ISNI:0000 0001 2164 3847); Louis Stokes Cleveland VA Medical Center, Cleveland, USA (GRID:grid.410349.b) (ISNI:0000 0004 5912 6484) 
 University of Bern, Institute of Pathology, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); University of Bern, Graduate School for Health Sciences, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157) 
 Weill Cornell Medical College, New York, USA (GRID:grid.5386.8) (ISNI:000000041936877X) 
 University of Bern, Institute of Pathology, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); Lausanne University Hospital and University of Lausanne, Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne, Switzerland (GRID:grid.8515.9) (ISNI:0000 0001 0423 4662) 
 Bristol Myers Squibb, New York, USA (GRID:grid.419971.3) (ISNI:0000 0004 0374 8313) 
 Yale University, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710) 
 New York University, New York, USA (GRID:grid.137628.9) (ISNI:0000 0004 1936 8753) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
ISSN
2397768X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2672845219
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.